Amidst a backdrop of fluctuating global markets, the U.S. technology sector has faced notable volatility, driven by competitive pressures in artificial intelligence and mixed corporate earnings ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...